Clinical Trials Logo

Filter by:
NCT ID: NCT00445250 Not yet recruiting - Radiodermatitis Clinical Trials

The Role of Calcipotriol as Radioprotector of Skin

Start date: n/a
Phase: Phase 2
Study type: Interventional

Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast. To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.

NCT ID: NCT00446537 Not yet recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder

Procedural Learning in Participants With ADHD

Start date: n/a
Phase: Phase 0
Study type: Interventional

Skill acquisition refers to the process of improvement of performance following practice experience. This process is the basis for generation of a long-lasting memory. Individuals with Attention Deficit Hyperactivity Disorder (ADHD) have been shown to be impaired on some performance aspects of previously learned skills, an impairment that is often ameliorated, at least temporarily, by psychostimulant medication (the standard therapy in ADHD). The proposed study aims to define the course of learning and of generation of long-term memory consolidation in individuals with ADHD, and to essay the effectiveness of psychostimulant medication on both the learning and retention of the skills.

NCT ID: NCT00451334 Not yet recruiting - Diabetes Clinical Trials

Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement

GS
Start date: n/a
Phase: Phase 2/Phase 3
Study type: Observational

This study is a prospective, open label, controlled, single center study. 40 patients will be recruited for the study, according to patients’ inflow and meeting eligibility criteria. Primary Goal * To evaluate the safety of the GlucoSat technology as a non-invasive blood glucose level measurement technology. Secondary Goal * To assess the efficacy of the GlucoSat technology as a non-invasive blood glucose level measurement technology.

NCT ID: NCT00463359 Not yet recruiting - Clinical trials for Basal Cell Carcinoma

A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone.

NCT ID: NCT00467662 Not yet recruiting - Clinical trials for Reccurent Herpes Labialis

Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)

Start date: n/a
Phase: Phase 4
Study type: Interventional

Recurrent cold sores - herpes simplex labialis (HSL) occurs in 20-40% of the US population and patient seek treatment because of the discomfort and visibility of the lesion although it is a self limiting disease. The purpose of this study is to check the safety, Efficacy and convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.

NCT ID: NCT00468026 Not yet recruiting - Clinical trials for Benign Prostatic Hyperplasia

Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this ex-vivo study is to evaluate the insertion procedure for the ProstaPlant implant in human prostates and the support that it supplies to the prostate.

NCT ID: NCT00471796 Not yet recruiting - Chest Pain Clinical Trials

A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Different Types of Functional Esophageal Disorders (Functional Heartburn and Functional Chest Pain)

Start date: n/a
Phase: N/A
Study type: Interventional

There is supposed that patients with functional esophageal disorders such as functional heartburns and functional chest pain have common underlying mechanisms of symptom generation. These include esophageal dysmotility, non-acidic gastro-esophageal reflux, duodeno-gastro-esophageal reflux, esophageal hypersensitivity, and psychological comorbidity. The treatment of these patients is the growing challenge in the primary care medicine and in the gastroenterological practice. It was postulated that functional disorders of the esophagus are the main reason for PPI failure in patients with heartburn. The aim of the study is to evaluate the role of biofeedback in the treatment of patients with functional chest pain and functional heartburns.

NCT ID: NCT00472147 Not yet recruiting - Arrhythmia Clinical Trials

Selection of Shock Energy in Out-Of-Hospital Cardiac Arrest

Start date: n/a
Phase: N/A
Study type: Interventional

Sudden cardiac death is the most frequent cause of death in industrialized countries. The most efficient interventiont in ventricular fibrillation is defibrillation in an appropriate timely manner. But since the intervention of defibrillation the optimal shock energy is unknown. As a too low energy is not able to terminate ventricular fibrillation a too high energy may cause asystole wich jeopardizes survival itself. We study the efficacy of different shock energies on the termination of ventricular fibrillatiion and survival.

NCT ID: NCT00473733 Not yet recruiting - Clinical trials for Diabetes Mellitus Type 2

Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2

GLP
Start date: n/a
Phase: Phase 4
Study type: Interventional

Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth. We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients. Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying. Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.

NCT ID: NCT00474591 Not yet recruiting - Clinical trials for Coronary Bypass Graft Failure/Occlusion

Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study

Fonda CABG
Start date: n/a
Phase: Phase 3
Study type: Interventional

(i) Main Research Question(s): What is the effect of fondaparinux on coronary graft patency, heart attack, stroke, and death in patients who have undergone coronary artery bypass grafting (CABG)? To reliably answer this question requires a large randomised trial. We propose a pilot study to demonstrate the feasibility of recruiting patients into this study and of performing CT angiograms to measure graft patency at 30 days. (ii) Why is this research important? Coronary artery bypass surgery has made a very important contribution to improving the health and survival of patients with advanced coronary artery disease but still has many problems. One in 10 patients experiences a heart attack at the time of surgery, 1 in 20 experiences a heart attack, stroke, or death during hospitalization, and 1 in 4 patients has at least 1 blocked graft within 1 year of surgery. Fondaparinux, a relatively new anticoagulant drug, has been shown to significantly reduce cardiovascular events and death in patients who have suffered a recent heart attack. Compared to established anticoagulant therapies for acute myocardial infarction, fondaparinux has been shown to be more effective with similar or lower risks of bleeding. Fondaparinux, unlike the most commonly used anticoagulants, does not cause Heparin Induced Thrombocytopenia (HIT), a rare condition with extremely high morbidity and mortality. This drug has never been studied in CABG patients. Our pilot study will provide key information about feasibility that will help us to design and perform a large definitive study in the future. (iii) What is being studied? We will be looking at blood flow in bypass grafts, heart attack, stroke, venous thromboembolism and death. For safety we will be looking at bleeding, transfusion, and need for further surgery because of bleeding. We will also perform laboratory tests for HIT antibodies as their levels are prognostic for the development of HIT and are also related to morbidity and mortality. The incidence of actual HIT cases will also be recorded.